Opportunity for Improved Menopausal Hormone Therapy Prescribing

Authors:

Abstract
This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.

This publication has 18 references indexed in Scilit: